“NuvOx Therapeutics, Inc. (“NuvOx”) and FYR Bio (“FYR”) today announced a collaboration pairing NuvOx’s Phase IIb glioblastoma trial of NanO₂ with FYR’s EV-based liquid-biopsy expertise to provide additional biomarker insights that support clinical development, through an NCI (a division of NIH) grant “Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic”.
Dr. Evan Unger, co-founder and Executive Chairman of NuvOx, said, “Biomarkers are a powerful tool to gain insights about a drug candidate’s effect and the tumor microenvironment. Our technology aims at reversing tumor hypoxia. This grant will enable us to study these factors, leveraging our Phase IIb Glioblastoma trial. We also hope that this study promotes the differentiation of pseudo-progression vs. true progression, a well-known challenge for treating Glioblastoma patients.”